

Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region - Global Forecast to 2027

Market Report | 2022-08-25 | 128 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The cardiac safety services market is projected to reach USD 1.0 Billion by 2027 from USD 0.6 Billion in 2022, at a CAGR of 11.2% during the forecast period. The increasing expenditure by pharmaceutical companies, alongside rising government spending is leading has driven the pace of R&D activity in this industry to develop new drugs. This will contribute to the need for numerous preclinical and clinical services during drug development, including cardiac safety evaluation.

"The Blood Pressure Measurement segment accounted for the second largest share of the type of services market in 2021" Blood pressure monitoring is an essential part of cardiac safety services. Increasing R&D activities and stringent clinical trial regulations make blood pressure measurement a critical parameter from both an efficacy and a safety endpoint. This factor is expected to drive the growth of this market segment.

"The contract research organizations (CROs) accounted for the second largest share of the end user market in 2021" CROs provide specialized services to pharmaceutical & biopharmaceutical companies at a low cost. As a result, many pharmaceutical & biopharmaceutical companies are outsourcing their drug discovery services to CROs. As cardiac safety services are critical in drug development processes, their adoption is expected to increase with an increase in outsourcing Laboratory Corporation of America Holdings (US), Koninklijke Philips N.V. (Netherlands), Clario (US), Banook Group (France), IQVIA (US), Biotrial (France), Certara (US), Celerion (US), Medpace (US), Ncardia (Netherlands), Richmond Pharmacology (UK), PhysioStim (France), Shanghai Medicilon (China), Pharmaceutical Product Development (US), and SGS (Switzerland) are some of the major players operating in the market.

"Europe: The second largest share in the cardiac safety services market"

The European market includes Germany, the UK, France, Italy, Spain, and the RoE. It accounted for the second largest market share of the cardiac safety services market. Important considerations include demographic changes, such as the growing incidence of chronic diseases is expected to drive the market growth in the region

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 80% and Demand Side - 20% -[By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25% - By Region: North America - 20%, Europe - 10%, Asia-Pacific - 55%, RoW - 15% List of Companies Profiled in the Report: - Laboratory Corporation of America Holdings (US) - Koninklijke Philips N.V. (Netherlands) -[Clario (US) Banook Group (France) - IQVIA (US) Biotrial (France) -[Certara (US) -[Celerion (US) Medpace (US) - Ncardia (Netherlands) - Richmond Pharmacology (UK) - PhysioStim (France) Shanghai Medicilon (China) - Pharmaceutical Product Development (US) - SGS (Switzerland) **Research Coverage:**

This report provides a detailed picture of the cardiac safety services market. It aims at estimating the size and future growth potential of the market across different segments such as the type, type of service, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cardiac safety services market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, challenges, trends, and opportunities.

Table of Contents:

1[INTRODUCTION[]20 1.1[]STUDY OBJECTIVES[]20 1.2[]MARKET DEFINITION[]20 1.3[]STUDY SCOPE[]21 FIGURE 1[]CARDIAC SAFETY SERVICES MARKET[]21 1.4[]YEARS CONSIDERED[]21 1.5[]CURRENCY CONSIDERED[]22

1.6 LIMITATIONS 22 1.7 STAKEHOLDERS 22 2 RESEARCH METHODOLOGY 23 2.1 RESEARCH DATA 23 FIGURE 2 RESEARCH DESIGN 23 2.1.1 SECONDARY DATA 23 2.1.1.1 Key data from secondary sources 24 2.1.2 PRIMARY DATA 25 2.1.2.1 Key data from primary sources 25 2.1.2.2 Key industry insights 26 FIGURE 3∏BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION∏26 2.2 MARKET SIZE ESTIMATION 27 2.2.1 BOTTOM-UP APPROACH FIGURE 4 BOTTOM-UP APPROACH 27 2.2.2 TOP-DOWN APPROACH 28 FIGURE 5⊓TOP-DOWN APPROACH⊓28 2.2.3 GROWTH FORECAST 28 2.3 DATA TRIANGULATION 29 FIGURE 6 DATA TRIANGULATION METHODOLOGY 29 2.4 RESEARCH ASSUMPTIONS 30 3 EXECUTIVE SUMMARY 31 FIGURE 7 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2022 VS. 2027 (USD MILLION) 31 FIGURE 8∏CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)∏32 FIGURE 9∏CARDIAC SAFETY SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)∏32 FIGURE 10 GEOGRAPHICAL SNAPSHOT OF CARDIAC SAFETY SERVICES MARKET 33 4 PREMIUM INSIGHTS 34 4.1□CARDIAC SAFETY SERVICES MARKET OVERVIEW□34 FIGURE 11 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE MARKET GROWTH 34 4.2 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SHARE, BY TYPE AND COUNTRY (2021) 35 FIGURE 12 INTEGRATED SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021 35 4.3 CARDIAC SAFETY SERVICES MARKET SHARE, BY TYPE OF SERVICE, 2022 VS. 2027 36 FIGURE 13 CCG/HOLTER MEASUREMENT SERVICES SEGMENT TO DOMINATE MARKET IN 2027 36 4.4 CARDIAC SAFETY SERVICES MARKET SHARE, BY END USER, 2022 36 FIGURE 14 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022[]36 4.5 CARDIAC SAFETY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 37 FIGURE 15 EUROPEAN COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 5 MARKET OVERVIEW 38 5.1 INTRODUCTION 38 5.2 MARKET DYNAMICS 38 FIGURE 16 CARDIAC SAFETY SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 38 5.2.1 || DRIVERS || 39 5.2.1.1 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry 39 FIGURE 17 GLOBAL PHARMACEUTICAL R&D SPENDING, 2012-2026 39 5.2.1.2 Increased outsourcing of R&D activities 39 FIGURE 18 ACTIVE PHARMACEUTICAL DRUG PIPELINE, JANUARY 2011 TO JANUARY 2021 40 5.2.1.3 Increasing number of clinical trials 40

FIGURE 19[INCREASING NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000-2021)[]41

5.2.2 OPPORTUNITIES 41

5.2.2.1 Introduction of new technologies and methods 41

5.2.2.2 Growth in biosimilars and biologics markets 42

5.2.3 CHALLENGES 42

5.2.3.1 High cost of cardiac safety evaluation 42

6 CARDIAC SAFETY SERVICES MARKET, BY TYPE 43

6.1 INTRODUCTION 44

TABLE 1 CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION) 44

6.2 INTEGRATED SERVICES 44

6.2.1 INTEGRATED SERVICES TO DOMINATE CARDIAC SAFETY SERVICES MARKET 44

TABLE 2[INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)[]44 TABLE 3[]NORTH AMERICA: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]45 TABLE 4[]EUROPE: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]45 TABLE 5[]ASIA PACIFIC: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]46 6.3[]STANDALONE SERVICES[]46

6.3.1 STANDALONE SERVICES SEGMENT WITNESSING GROWTH DUE TO COST-EFFECTIVENESS 46

TABLE 6 STANDALONE CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION) 46

TABLE 7 NORTH AMERICA: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 47

TABLE 8[]EUROPE: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]47

TABLE 9]ASIA PACIFIC: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)]48 7]CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE]49

7.1 INTRODUCTION 50

TABLE 10 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION) 50

7.2 ECG/HOLTER MEASUREMENT SERVICES 50

7.2.1[]ECG/HOLTER MEASUREMENT SERVICES SUPPORT R&D IN NOVEL METHODS FOR CLINICAL TRIALS AND DRUG DISCOVERY[]50 TABLE 11[]ECG/HOLTER MEASUREMENT SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)[]51

TABLE 12[]NORTH AMERICA: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]51 TABLE 13[]EUROPE: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]51 TABLE 14[]ASIA PACIFIC: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]52 7.3[]BLOOD PRESSURE MEASUREMENT SERVICES[]52

7.3.1 INCREASING R&D ACTIVITIES TO DRIVE MARKET GROWTH 52

TABLE 15[BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)]52 TABLE 16[NORTH AMERICA: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)]53 TABLE 17[EUROPE: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)]53 TABLE 18[ASIA PACIFIC: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)]53 7.4]CARDIOVASCULAR IMAGING SERVICES]54

7.4.1 CARDIOVASCULAR IMAGING SERVICES HELP IN DRUG EVALUATION 54

TABLE 19 CARDIOVASCULAR IMAGING SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION) 54

TABLE 20[]NORTH AMERICA: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]54 TABLE 21[]EUROPE: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]55 TABLE 22[]ASIA PACIFIC: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]55

7.5[]THOROUGH QT STUDIES[]55

7.5.1]NEED TO MEET STRINGENT REGULATORY REQUIREMENTS TO DRIVE DEMAND FOR THOROUGH QT STUDIES]55 TABLE 23]THOROUGH QT STUDIES MARKET, BY REGION, 2020-2027 (USD MILLION)]56

TABLE 24 NORTH AMERICA: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 56 TABLE 25 EUROPE: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 57

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

TABLE 26□ASIA PACIFIC: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)□57 7.6 OTHER SERVICES 58 TABLE 27 OTHER CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION) 58 TABLE 28[]NORTH AMERICA: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]58 TABLE 29∏EUROPE: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)∏59 TABLE 30 ASIA PACIFIC: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 59 8 CARDIAC SAFETY SERVICES MARKET, BY END USER 60 8.1 INTRODUCTION 61 TABLE 31 CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION) 61 8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 61 8.2.1∏INCREASING R&D BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE DEMAND FOR CARDIAC SAFETY SERVICES[61 TABLE 32 CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020-2027 (USD MILLION)∏62 TABLE 33[]NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION) 62 TABLE 34 UROPE: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)[62 TABLE 35[]ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION) 63 8.3 CONTRACT RESEARCH ORGANIZATIONS 63 8.3.1□INCREASING OUTSOURCING OF DRUG DISCOVERY PROCESSES TO SUPPORT SEGMENT GROWTH□63 TABLE 36[]CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION)[63 TABLE 37[NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)[64 TABLE 38[]EUROPE: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)∏64 TABLE 39]ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)[65 9 CARDIAC SAFETY SERVICES MARKET, BY REGION ☐66 9.1 INTRODUCTION 67 TABLE 40⊓CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)∏67 9.2 NORTH AMERICA 67 FIGURE 20 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SNAPSHOT 68 TABLE 41∏NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)∏69 TABLE 42∏NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)∏69 TABLE 43[NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)[69 TABLE 44∏NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)∏70 9.2.1 US 70 9.2.1.1 US dominates global cardiac safety services market 70 TABLE 45[]US: TOTAL NUMBER OF CLINICAL TRIALS (2019)[]70 TABLE 46[IUS: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)[]71 TABLE 47⊓US: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)∏71 TABLE 48∏US: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)∏71 9.2.2 CANADA 72 9.2.2.1 Canada has high-quality clinical trial infrastructure and expertise 72

TABLE 49[]CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)[]72 TABLE 50[]CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]73 TABLE 51[]CANADA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)[]73 9.3[]EUROPE[]73

FIGURE 21[]EUROPE: CARDIAC SAFETY SERVICES MARKET SNAPSHOT[]74

TABLE 52[]EUROPE: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]75 TABLE 53[]EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)[]75 TABLE 54[]EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]75 TABLE 55[]EUROPE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)[]76 9.3.1[]GERMANY[]76

9.3.1.1 Availability of skilled staff and flexible labor laws have made Germany a popular EU hub for clinical trials 76 TABLE 56 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION) 77 TABLE 57 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION) 77 TABLE 58 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION) 77 9.3.2 UK 78

9.3.2.1 Steady growth of pharmaceutical R&D expenditure indicates favorable prospects for cardiac safety services 78 TABLE 59 UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION) 78 TABLE 60 UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION) 79 TABLE 61 UK: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION) 79 9.3.3 FRANCE

9.3.3.1 High clinical trial activity for cancer therapies to drive market growth 79 TABLE 62 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION) 80 TABLE 63 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION) 80 TABLE 64 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION) 80 9.3.4 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION) 80

9.3.4.1 Strong pharma industry and availability of funding for drug development fuel market growth 81 TABLE 65 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021) 81 TABLE 66 ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION) 82 TABLE 67 ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION) 82 TABLE 68 ITALY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION) 82 9.3.5 SPAIN 83

9.3.5.1 Growing investment in pharmaceutical R&D and a favorable climate for approvals boost market growth 83 TABLE 69 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION) 83 TABLE 70 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION) 84 TABLE 71 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION) 84 9.3.6 REST OF EUROPE 84

TABLE 72[ROE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)[]85 TABLE 73[]ROE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]85 TABLE 74[]ROE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)[]86 9.4[]ASIA PACIFIC[]86

TABLE 75[]APAC: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]87 TABLE 76[]APAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)[]87 TABLE 77[]APAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]87 TABLE 78[]APAC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)[]88 9.4.1[]CHINA[]88

9.4.1.1 China dominates APAC market for cardiac safety services 88

TABLE 79[CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)[88

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

TABLE 80[]CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]89 TABLE 81 CHINA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION) 89 9.4.2 || APAN || 89 9.4.2.1 Strong IP rights and supportive policies have strengthened R&D sector in Japan 89 TABLE 82[]APAN: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)[]90 TABLE 84∏JAPAN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)∏90 9.4.3 || INDIA || 91 9.4.3.1 [Lack of language barriers and availability of trained resources make India an attractive destination for clinical trials[91 TABLE 85[INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)[91 TABLE 86 INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION) 91 TABLE 87[INDIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)[]92 9.4.4 AUSTRALIA 92 9.4.4.1 Favorable R&D tax incentives and cash rebates have driven clinical trial activity in Australia TABLE 88∏AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)∏92 TABLE 89/TAUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)/193 TABLE 90[]AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)[]93 9.4.5 REST OF ASIA PACIFIC 93 TABLE 91 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION) 94 TABLE 92∏ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)∏94 TABLE 93∏ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)∏94 9.5 REST OF THE WORLD 95 TABLE 94 ROW: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION) 96 TABLE 95∏ROW: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)∏96 TABLE 96∏ROW: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)∏96 10 COMPETITIVE LANDSCAPE 97 10.1 OVERVIEW 97 FIGURE 22 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2019-2022 97 10.2 MARKET PLAYER RANKING 98 TABLE 97 GLOBAL CARDIAC SAFETY SERVICES MARKET PLAYER RANKING, 2021 98 10.3 COMPETITIVE LEADERSHIP MAPPING 99 10.3.1 VISIONARY LEADERS 99 10.3.2 DYNAMIC DIFFERENTIATORS 99 10.3.3 INNOVATORS 99 10.3.4 EMERGING COMPANIES 99 FIGURE 23 CARDIAC SAFETY SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING 100 10.4 COMPETITIVE SITUATION AND TRENDS 101 10.4.1 ACQUISITIONS 101 TABLE 98 ACQUISITIONS, 2019-2022 101 10.4.2 PARTNERSHIPS, ALLIANCES, AND AGREEMENTS 101 TABLE 99[PARTNERSHIPS, ALLIANCES, AND AGREEMENTS, 2019-2022[101 10.4.3 EXPANSIONS 101 TABLE 100 EXPANSIONS, 2019-2022 101 10.4.4 OTHER STRATEGIES 102 TABLE 101 OTHER STRATEGIES, 2019-2022 102 ? 11 COMPANY PROFILES 103

(Business overview, Products offered, Recent Developments, MNM view)* 11.1 KEY PLAYERS 103 11.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS 103 TABLE 102 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW 103 FIGURE 24 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT 104 11.1.2 KONINKLIJKE PHILIPS 106 TABLE 103 KONINKLIJKE PHILIPS: BUSINESS OVERVIEW 106 FIGURE 25 KONINKLIJKE PHILIPS: COMPANY SNAPSHOT 107 11.1.3 CLARIO 109 TABLE 104 CLARIO: BUSINESS OVERVIEW 109 11.1.4 BANOOK GROUP 111 TABLE 105 BANOOK GROUP: BUSINESS OVERVIEW 111 11.1.5 || QVIA || 112 TABLE 106 IQVIA: BUSINESS OVERVIEW 112 FIGURE 26 IQVIA: COMPANY SNAPSHOT 113 11.1.6 BIOTRIAL 115 TABLE 107 BIOTRIAL: BUSINESS OVERVIEW 115 11.1.7 CERTARA 116 TABLE 108 CERTARA: BUSINESS OVERVIEW 116 FIGURE 27 CERTARA: COMPANY SNAPSHOT 117 11.1.8 CELERION 118 TABLE 109 CELERION: BUSINESS OVERVIEW 118 11.1.9 || MEDPACE || 119 TABLE 110 MEDPACE: BUSINESS OVERVIEW 119 FIGURE 28 MEDPACE: COMPANY SNAPSHOT 119 11.1.10 NCARDIA 121 TABLE 111 NCARDIA: BUSINESS OVERVIEW 121 11.1.11 RICHMOND PHARMACOLOGY 122 TABLE 112 RICHMOND PHARMACOLOGY: BUSINESS OVERVIEW 122 11.1.12 PHYSIOSTIM 123 TABLE 113 PHYSIOSTIM: BUSINESS OVERVIEW 123 11.2 OTHER PLAYERS 124 11.2.1 SHANGHAI MEDICILON 124 11.2.2 PHARMACEUTICAL PRODUCT DEVELOPMENT LLC. 124 11.2.3 SGS S.A. 125 *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies. ? 12 APPENDIX 126 12.1 DISCUSSION GUIDE 126 12.2[KNOWLEDGESTORE: MARKETSANDMARKETS? SUBSCRIPTION PORTAL]129 12.3 CUSTOMIZATION OPTIONS 131

12.4 RELATED REPORTS 131

12.5 AUTHOR DETAILS 132



Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region - Global Forecast to 2027

Market Report | 2022-08-25 | 128 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License		Price
	Single User		\$4950.00
	Multi User		\$6650.00
	Corporate License		\$8150.00
	Enterprise Site License		\$10000.00
		VAT	
		Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		
Company Name*	EU Vat / Tax ID / NIF	number*
Address*	City*	

7in	Code*
Zip	Code

Country*

Date

Signature

2025-05-20